Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6075181

Title:Human antibodies derived from immunized xenomice
Inventors:Kucherlapati, Raju; Darien, CT, USA
Jakobovits, Aya; Menlo Park, CA, USA
Klapholz, Sue; Stanford, CA, USA
Brenner, Daniel G.; San Mateo, CA, USA
Capon, Daniel J.; Hillsborough, CA, USA
Summary:This invention describes a novel transgenic mouse which has been modified to produce fully human IgG2 heavy chains specific for desired antigen, IL-8, when immunized with IL-8, and whose endogenous loci has been disabled. Human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to an antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof. This invention relates to a transgenic mouse wherein all of the somatic and germ cells comprise a DNA fragment of human chromosome 14 from the five most proximal VH gene segments, continuing through the D segment genes, the J segment genes and the constant region genes through C?d of the human immunoglobulin heavy chain locus, wherein this fragment does not contain a gene in question, and wherein the fragment is operably linked to a the corresponding human region gene. This represents an extension of other applications filed by the same assignee and inventor.
Abstract:Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6075181
Application Number:US1995000486857
Date Filed:07/06/1995
Date Published:13/06/2000
Assignee:Abgenix, Inc., Fremont, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/5/2020